B
SRPT icon

Baird’s Sarepta Therapeutics SRPT Stock Holding History

Baird’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-13,345
Closed -$630K – 1138
2013
Q3 		$630K Buy
13,345
+5,275
+65% +$203K 0.01% 707
2013
Q2 		$307K Buy
+8,070
New +$289K 0.01% 899

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Baird's SRPT Position: Q4 2013 in Review

Baird sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 13,345 shares — an estimated $630K sold.

Baird first reported a position in SRPT in Q2 2013 and held it in 2 quarters. The position peaked at $630K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

  • Baird reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Baird sold 13,345 Sarepta Therapeutics shares in Q4 2013, an estimated $630K.
  • Baird first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 2 quarters.
  • Baird's Sarepta Therapeutics position peaked at $630K in Q3 2013.
  • 108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on Baird's 13F filing for Q4 2013, filed 12 Feb 2014.